Immucell annual debt-to-ebitda ratio
2012
2013
2017
2018
2019
2020
2021
2022
2024
2025
Immucell Debt-to-EBITDA Ratio Growth & History (ICCC)
Immucell's debt-to-ebitda ratio was 2.98 for fiscal 2025.
View full Immucell company overviewImmucell annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.98 | −10.88 | −78.52% |
| 2024 | 2024-12-31 | 13.86 | — | — |
| 2022 | 2022-12-31 | 66.16 | 65.80 | +18410.42% |
| 2021 | 2021-12-31 | 0.36 | −10.74 | −96.78% |
| 2020 | 2020-12-31 | 11.10 | 4.69 | +73.13% |
| 2019 | 2019-12-31 | 6.41 | −118.56 | −94.87% |
| 2018 | 2018-12-31 | 124.98 | 111.44 | +823.25% |
| 2017 | 2017-12-31 | 13.54 | — | — |
| 2013 | 2013-12-31 | 2.35 | 0.54 | +29.70% |
| 2012 | 2012-12-31 | 1.81 | — | — |
Immucell quarterly debt-to-ebitda ratio
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q4.17
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.98 | −1.20 | −37.66% |
| Q1 2026 | 2026-03-31 | 2.49 | −2.71 | −52.11% |
| Q4 2025 | 2025-12-31 | 2.98 | −10.88 | −78.52% |
| Q3 2025 | 2025-09-30 | 2.66 | — | — |
| Q2 2025 | 2025-06-30 | 3.18 | — | — |
| Q1 2025 | 2025-03-31 | 5.20 | — | — |
| Q4 2024 | 2024-12-31 | 13.86 | — | — |
| Q3 2022 | 2022-09-30 | 6.48 | 5.78 | +833.83% |
| Q2 2022 | 2022-06-30 | 4.15 | 3.04 | +273.27% |
| Q1 2022 | 2022-03-31 | 0.49 | −22.63 | −97.87% |
| Q4 2021 | 2021-12-31 | 0.36 | −10.74 | −96.78% |
| Q3 2021 | 2021-09-30 | 0.69 | −7.70 | −91.74% |
| Q2 2021 | 2021-06-30 | 1.11 | −9.06 | −89.07% |
| Q1 2021 | 2021-03-31 | 23.13 | 15.14 | +189.76% |
| Q4 2020 | 2020-12-31 | 11.10 | 4.69 | +73.13% |
| Q3 2020 | 2020-09-30 | 8.39 | −5.18 | −38.16% |
| Q2 2020 | 2020-06-30 | 10.17 | −1.92 | −15.87% |
| Q1 2020 | 2020-03-31 | 7.98 | −3.32 | −29.36% |
| Q4 2019 | 2019-12-31 | 6.41 | −118.56 | −94.87% |
| Q3 2019 | 2019-09-30 | 13.58 | −20.07 | −59.65% |
| Q2 2019 | 2019-06-30 | 12.09 | — | — |
| Q1 2019 | 2019-03-31 | 11.30 | — | — |
| Q4 2018 | 2018-12-31 | 124.98 | 111.44 | +823.25% |
| Q3 2018 | 2018-09-30 | 33.65 | — | — |
| Q4 2017 | 2017-12-31 | 13.54 | — | — |
| Q1 2014 | 2014-03-31 | 9.20 | 7.58 | +465.33% |
| Q4 2013 | 2013-12-31 | 2.35 | 0.54 | +29.70% |
| Q3 2013 | 2013-09-30 | 1.67 | −0.20 | −10.68% |
| Q2 2013 | 2013-06-30 | 1.56 | −0.73 | −31.96% |
| Q1 2013 | 2013-03-31 | 1.63 | — | — |
| Q4 2012 | 2012-12-31 | 1.81 | — | — |
| Q3 2012 | 2012-09-30 | 1.87 | — | — |
| Q2 2012 | 2012-06-30 | 2.30 | — | — |
Immucell debt-to-ebitda ratio trends
Over the last five fiscal years, Immucell's debt-to-ebitda ratio decreased from 11.10 to 2.98, a change of −8.12. The latest reported quarter, Q2 2026, shows 1.98.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immucell source filings ↗